- Home
- MNOV vs MGNX Comparison
MNOV vs MGNX Comparison
Compare MNOV & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- MGNX
- Stock Information
- Founded
- MNOV 2000
- MGNX 2000
- Country
- MNOV United States
- MGNX United States
- Employees
- MNOV N/A
- MGNX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- MGNX Health Care
- Exchange
- MNOV Nasdaq
- MGNX Nasdaq
- Market Cap
- MNOV 76.0M
- MGNX 70.3M
- IPO Year
- MNOV 2005
- MGNX 2013
- Fundamental
- Price
- MNOV $1.49
- MGNX $1.71
- Analyst Decision
- MNOV Strong Buy
- MGNX Hold
- Analyst Count
- MNOV 1
- MGNX 10
- Target Price
- MNOV $9.00
- MGNX $6.83
- AVG Volume (30 Days)
- MNOV 14.9K
- MGNX 1.1M
- Earning Date
- MNOV 05-08-2025
- MGNX 05-08-2025
- Dividend Yield
- MNOV N/A
- MGNX N/A
- EPS Growth
- MNOV N/A
- MGNX N/A
- EPS
- MNOV N/A
- MGNX N/A
- Revenue
- MNOV N/A
- MGNX $149,962,000.00
- Revenue This Year
- MNOV N/A
- MGNX N/A
- Revenue Next Year
- MNOV N/A
- MGNX $80.86
- P/E Ratio
- MNOV N/A
- MGNX N/A
- Revenue Growth
- MNOV N/A
- MGNX 155.26
- 52 Week Low
- MNOV $1.12
- MGNX $0.99
- 52 Week High
- MNOV $2.55
- MGNX $16.59
- Technical
- Relative Strength Index (RSI)
- MNOV 54.28
- MGNX 57.37
- Support Level
- MNOV $1.36
- MGNX $1.10
- Resistance Level
- MNOV $1.52
- MGNX $1.34
- Average True Range (ATR)
- MNOV 0.10
- MGNX 0.16
- MACD
- MNOV 0.03
- MGNX 0.09
- Stochastic Oscillator
- MNOV 92.31
- MGNX 90.00
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.